KBC Group NV Sells 61,835 Shares of Hologic, Inc. $HOLX

KBC Group NV reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 63.6% during the second quarter, Holdings Channel reports. The firm owned 35,398 shares of the medical equipment provider’s stock after selling 61,835 shares during the quarter. KBC Group NV’s holdings in Hologic were worth $2,307,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Chung Wu Investment Group LLC purchased a new position in shares of Hologic during the second quarter valued at about $26,000. Caitong International Asset Management Co. Ltd boosted its position in Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 273 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of Hologic during the 1st quarter worth approximately $34,000. Cromwell Holdings LLC raised its position in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 436 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Hologic in the 1st quarter valued at approximately $42,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Hologic

In other news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This represents a 10.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.88% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on HOLX. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Evercore ISI set a $78.00 target price on shares of Hologic and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Morgan Stanley lifted their price target on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $79.77.

Hologic Stock Down 0.1%

HOLX opened at $74.15 on Monday. The stock has a market capitalization of $16.49 billion, a price-to-earnings ratio of 30.77, a PEG ratio of 2.54 and a beta of 0.65. The firm has a 50 day moving average price of $69.76 and a 200-day moving average price of $65.78. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $80.31. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the prior year, the business earned $1.01 earnings per share. Hologic’s revenue for the quarter was up 6.2% compared to the same quarter last year. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.